Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Richman

Showing results (111-120 of 210) with videos related to

Pageof 21
Sort By:
Cancer Treatment Reports|May 1, 1977
Phase I study of immunotherapy with methanol extraction residue (MER) of bacillus Calmette-GuérinS P Richman, J U Gutterman, E M Hersh, et al.
Cancer|December 1, 1975
Successful control of systemic Aspergillus niger infections in two patients with acute leukemiaF G Gercovich, S P Richman, V Rodriguez, et al.
Annals of the New York Academy of Sciences|November 1, 2003
Three forms of immune myastheniaMark A Agius, David P Richman, Robert H Fairclough, et al.
Investigational New Drugs|January 1, 1994
Phase II trial of trimetrexate in untreated advanced gastric carcinoma. A Southwest Oncology Group studyA Hantel, C M Tangen, J S Macdonald, et al.
Journal of the Royal Society of Medicine|August 18, 1999
Bone marrow involvement in breast cancer detected by positron emission tomographyC R Lewanski, G R Kaplan, J Potter, et al.
Cancer|January 15, 1991
A phase II multi-institutional trial of low-dose N-(phosphonacetyl)-L-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. A Southwest Oncology Group studyL M Morrell, A Bach, S P Richman, et al.
American Journal of Surgery|October 1, 1977
Results of BCG adjuvant immunotherapy in 100 patients with epidermoid carcinoma of the head and neckJ Y Suen, S P Richman, R B Livingston, et al.
Clinical Lung Cancer|May 16, 2019
Immune Checkpoint Inhibitor-Induced Myasthenia Gravis in a Patient with Advanced NSCLC and Remote History of ThymomaMatthew S Lara, Alaa Afify, Michael P Ellis, et al.
Cellular Immunology|August 15, 1980
Reduced T-lymphocyte cell reactivity as a function of human agingJ P Antel, J J Oger, E Dropcho, et al.
Investigational New Drugs|January 1, 1996
Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-fluorouracil in advanced gastric adenocarcinoma. A Southwest Oncology Group studyR L Martino, T R Fleming, L M Morrell, et al.
Pageof 21

Showing results (111-120 of 210) with videos related to

Sort By:
Pageof 21
Cancer Treatment Reports|May 1, 1977
Phase I study of immunotherapy with methanol extraction residue (MER) of bacillus Calmette-GuérinS P Richman, J U Gutterman, E M Hersh, et al.
Cancer|December 1, 1975
Successful control of systemic Aspergillus niger infections in two patients with acute leukemiaF G Gercovich, S P Richman, V Rodriguez, et al.
Annals of the New York Academy of Sciences|November 1, 2003
Three forms of immune myastheniaMark A Agius, David P Richman, Robert H Fairclough, et al.
Investigational New Drugs|January 1, 1994
Phase II trial of trimetrexate in untreated advanced gastric carcinoma. A Southwest Oncology Group studyA Hantel, C M Tangen, J S Macdonald, et al.
Journal of the Royal Society of Medicine|August 18, 1999
Bone marrow involvement in breast cancer detected by positron emission tomographyC R Lewanski, G R Kaplan, J Potter, et al.
Cancer|January 15, 1991
A phase II multi-institutional trial of low-dose N-(phosphonacetyl)-L-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. A Southwest Oncology Group studyL M Morrell, A Bach, S P Richman, et al.
American Journal of Surgery|October 1, 1977
Results of BCG adjuvant immunotherapy in 100 patients with epidermoid carcinoma of the head and neckJ Y Suen, S P Richman, R B Livingston, et al.
Clinical Lung Cancer|May 16, 2019
Immune Checkpoint Inhibitor-Induced Myasthenia Gravis in a Patient with Advanced NSCLC and Remote History of ThymomaMatthew S Lara, Alaa Afify, Michael P Ellis, et al.
Cellular Immunology|August 15, 1980
Reduced T-lymphocyte cell reactivity as a function of human agingJ P Antel, J J Oger, E Dropcho, et al.
Investigational New Drugs|January 1, 1996
Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-fluorouracil in advanced gastric adenocarcinoma. A Southwest Oncology Group studyR L Martino, T R Fleming, L M Morrell, et al.
Pageof 21